

## EFPIA Disclosure Report – 2021 Data – Netherlands

	Data disclosure form (Currency EUR)												
												2021 HCP/HCO Disclosure of publication: 30/10/2024	
	Full name	HCPs: City of Principal Practice HCOs: City where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier (OPTIONAL)		Contribution to costs of Events			Fee for service and consultancy			
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event		Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
-S					OTHER, NOT INCL	UDED ABOVE - where information can	not be disclosed on an individual bas	sis for legal reasons					
오	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A	0,00	0,00	0,00	0,00	Optional	
	Number of Recipients in aggregate disclosure					N/A	N/A	0	0	0	0	N/A	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					N/A	N/A	0%	0%	0%	0%	N/A	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
0-s	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
운	Aggregate amount attributable to transfers of value to such Recipients						0,00	0,00	0,00	0,00	0,00	Optional	
	Number of Recipients in aggregate disclosure						0	0	0	0	0	N/A	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					0%	0%	0%	0%	0%	0%	N/A	

Ç.D	AGGREGATE DISCLOSURE	
R8	Transfers of Value re Research & Development as defined	1 634 775,90